c19early.org COVID-19 treatment researchCOVID-19 treatments

rNAPc2 for COVID-19: real-time analysis

c19early.org

rNAPc2 for COVID-19

1 study with 156 patients

Serious outcome risk

rNAPc2

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 rNAPc2 studies · November 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−65%

Mortality (1)−65%

RCTs (1)−65%

Late (1)−65%

00.511.5+

← rNAPc2
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Aug 31 2023	Hess et al., Arteriosclerosis, Thrombosis, and Vascular Biology, doi:10.1161/ATVBAHA.122.318748	Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
Aug 31 2023	65% higher mortality (p=0.32). RCT 160 hospitalized COVID-19 patients showing no significant improvements with rNAPc2 (recombinant nematode anticoagulant protein c2) vs. heparin.

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

rNAPc2 for COVID-19: real-time analysis